The HSP90AA1 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population that disrupts the HSP90AA1 gene in HeLa cells, creating a loss-of-function model for the HSP90?? chaperone. This heterogeneous pool of edited cells circumvents clonal selection artifacts and captures genetic diversity, enabling studies of HSP90?? ablation in a cancer-relevant context. Supplied as a ready-to-use reagent, the polyclonal knockout cells facilitate robust interrogation of chaperone-dependent signaling without additional engineering.
The HeLa host cell line is an immortalized HPV18-positive cervical adenocarcinoma derived from Henrietta Lacks. These cells are aneuploid and telomerase-positive, widely used as a cancer model for cervical oncogenesis, viral-host interactions, and signal transduction research. The HPV E6 and E7 oncoproteins disrupt p53 and retinoblastoma pathways, creating an environment of proteotoxic stress and hyperactivated kinase signaling that depends heavily on HSP90 chaperone function.
HSP90AA1 encodes the constitutively active HSP90?? protein, an ATP-dependent chaperone that stabilizes and activates numerous oncogenic clients, including AKT, RAF, EGFR, HER2, CDK4, HIF-1??, and mutant p53. HSP90?? operates within a multichaperone complex involving HSP70, HOP/STIP1, p23/PTGES3, AHA1, CDC37, and immunophilins such as FKBP51/52. Its activity is induced by HSF1, cellular stress, AKT, and CK2 kinase. Consequently, HSP90?? integrates signals across PI3K/AKT, MAPK/ERK, JAK/STAT, and NF-??B pathways. Gene disruption leads to client protein misfolding, proteasomal degradation, and suppression of parallel oncogenic circuits.
In HeLa cells, HSP90AA1 knockout destabilizes critical signaling nodes, including AKT and EGFR, thereby attenuating survival and proliferation. The HPV-transformed and aneuploid background imposes heightened proteotoxic stress, rendering these cells especially dependent on HSP90-mediated protein homeostasis. The polyclonal knockout population thus models tumor heterogeneity and can reveal compensatory adaptations or subpopulation selection pressures upon loss of chaperone function.
Key applications include functional studies of HSP90??, chaperone-targeted drug screening, and client protein stability validation. Representative assays comprise western blotting for client abundance, phospho-signaling analysis, co-immunoprecipitation of chaperone complexes, flow cytometry for cell cycle and apoptosis, and viability assays. The cells also support research into stress responses and viral oncogenesis. For further details, contact Ascent Research.
